Microbot Medical CEO to Discuss LIBERTY FDA Clearance and Commercialization on Benzinga Interview Sept 24

Microbot Medical Inc.

CEO Harel Gadot will be interviewed on Benzinga All Access at 10:45am ET on September 24, 2025.
Discussion will cover recent FDA 510(k) clearance of the LIBERTY Endovascular Robotic System.
FDA clearance for LIBERTY was announced on September 8, 2025.
Company plans for U.S. commercialization of the peripheral endovascular system.
LIBERTY is described as the first single-use, remotely operated robotic solution for endovascular procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.